SymBio PharmaceuticalsSYMQY -12.42%35 Gross Margin % is 74.81% as of Dec. 2025, which is 38% above its 10-year median of 54.23. GuruFocus rates SYMQY with a GF Score™ of 35/100 and a GF Value™ of $0.50. The stock has 6 warning signs investors should review. Among 936 Drug Manufacturers companies, SymBio Pharmaceuticals ranks better than 84.29% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
SymBio Pharmaceuticals had a gross margin of 74.81% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
SymBio Pharmaceuticals Gross Margin % Related Terms
SymBio Pharmaceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for SymBio Pharmaceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SymBio Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SymBio Pharmaceuticals Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SymBio Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where SymBio Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
SymBio Pharmaceuticals (SYMQY) has a Gross Margin % of 74.81% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on SymBio Pharmaceuticals and its competitors. This is 38% above median its historical median of 54.23. Over the past decade, SymBio Pharmaceuticals' Gross Margin % has ranged from 29.02 to 78.91. According to the industry distribution chart, SymBio Pharmaceuticals ranks #147 out of 936 companies in the Drug Manufacturers industry, placing it in the top 15.7%.
Is SymBio Pharmaceuticals' Gross Margin % too high?
SymBio Pharmaceuticals' current Gross Margin % of 74.81% is 38% above median its 10-year median of 54.23. Over the past 10 years, this metric has ranged from a low of 29.02 to a high of 78.91. The Drug Manufacturers industry median Gross Margin % is 48.50. SymBio Pharmaceuticals' value of 74.81% is 54.2% above this industry median. Based on the distribution chart, SymBio Pharmaceuticals ranks #147 out of 936 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, SymBio Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, SymBio Pharmaceuticals ranks #147 out of 936 companies for Gross Margin %. This places SymBio Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.50. SymBio Pharmaceuticals' value of 74.81% is 54.2% above this benchmark. Historically, SymBio Pharmaceuticals' own Gross Margin % has ranged from 29.02 to 78.91 over the past decade. While the company's 10-year median is 54.23 vs. the industry median of 48.50, SymBio Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.50, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SymBio Pharmaceuticals's current Gross Margin % of 74.81% is 54.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on SymBio Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SymBio Pharmaceuticals's current Gross Margin % is 74.81%, which is 38% above median its own 10-year median of 54.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
SymBio Pharmaceuticals (SYMQY) has a current Gross Margin % of 74.81%. The stock's GF Value™ is $0.50, compared to a current price of $0.56 — trading 11.6% above its estimated fair value. The current Gross Margin % is 74.81%, which is 38% above median its 10-year median of 54.23 and 54.2% above the Drug Manufacturers industry median of 48.50. SymBio Pharmaceuticals' overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For SymBio Pharmaceuticals (SYMQY), the current Gross Margin % is 74.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SymBio Pharmaceuticals (SYMQY) Overvalued in 2026?
Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued.
The current stock price of $0.56 is trading 11.6% above its estimated GF Value™ of $0.50.
Key valuation signals for SYMQY:
Gross Margin %: 74.81% (38% above median its 10-year median of 54.23)
GF Value™: $0.50 vs. price of $0.56 (11.6% above fair value)
Industry Position: 54.2% above the Drug Manufacturers median (#147 of 936)
No single metric tells the full story. See the SYMQY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
35GF Score
Get the complete analysis for SYMQY
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SYMQY has been successfully added to your 
